The current COVID-19 pandemic has raised interest in whether there are changes in either the role or safety of ultrasound enhancing agents (UEAs) in echocardiography. This Webinar from experts in the practice of contrast echocardiography will address:
- The impact of UEAs in patients with known or suspected COVID-19.
- Modifications to standard protocols for performing contrast ultrasound on patients who are in high-risk isolation settings.
- Safety of UEAs in patients who are critically ill or who are known to have COVID-19.
- Recognize situations where ultrasound enhancing agents (UEAs) are likely to have a clinical impact on the general population and on patients with known or suspected COVID-19.
- Be able to apply procedural modifications for efficient and safe use of (UEAs) in COVID-19 patients who are in isolation and at high risk for transmitting the disease.
- Understand the biologic basis underlying safety of (UEAs) and how they apply to the COVID-19 setting.
This program has been designed for physicians with an interest in cardiac imaging (including, but not limited to, cardiologists, interventional cardiologists, cardiac, thoracic, and vascular surgeons), nurses, and other healthcare professionals involved in echocardiography who are looking for AMA PRA Category 1 Credit(s)TM
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. Northwest Imaging Forums is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NWIF designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Available from 05/07/2022 | Expires: 05/07/2023
0.75 AMA PRA Category 1 Credits™
As an accredited provider of continuing medical education, it is the policy of Northwest Imaging Forums, Inc. (NWIF) to ensure balance, independence, objectivity, and scientific rigor in all of its activities. In accordance with this policy, faculty and planners must disclose any financial relationships with commercial interests germane to program content. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of NWIF to ensure that the COI is resolved in order to ensure the integrity of the CME activity. The planner has nothing to disclose.
Jonathan R. Lindner, MD, FACC, FASE
- Nothing to disclose.
Thomas R. Porter, MD, FACC, FASE
- Speaker: Northwest Imaging Forums
- Consultant: Lantheus Medical
- Research Equipment Support: Philips Healthcare
Michelle Bierig, PhD, ACS, RDCS, RCS, CPHQ, FASE, AACC – reported no relevant relationships with entities producing health care goods or services
Jonathan R. Lindner, MD, FACC, FASE
M. Lowell Edwards Professor of Cardiology,
Oregon Health and Science University
Portland, Oregon
Thomas R. Porter, MD, FACC, FASE
Professor of Medicine
Theodore F. Hubbard Distinguished Chair of Cardiology
University of Nebraska Medical Center
Division of Cardiovascular Medicine – Omaha, Nebraska
Michelle Bierig
PhD, ACS, RDCS, RDMS, RCS, CPHQ, FSDMS, FASE, AACC
Director, Cardiovascular at Hillcrest South
Hillcrest Healthcare System
Tulsa, Oklahoma
